Hanwha Offers Up to $1.2 Billion for Austal US Business 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Airbus Joins Air India A320 Altitude Drop Probe 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
ADNOC Gas Targets Up to $4B Profit in 2026 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its fourth quarter and full year 2017 financial results will be reported on Tuesday, February 27, 2018.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at https://biocryst.gcs-web.com/financial-information/sec-filings.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
